7/15/2020 8:18:45 AM
Idera Plans Private Placement Of Up To $20.0 Mln
3/5/2020 7:17:19 AM
Idera Completes Enrollment In Registrational Trial Of Tilsotolimod In Combination With Ipilimumab
1/14/2020 7:10:41 AM
Idera Provides Corporate Outlook For 2020
10/21/2019 7:11:04 AM
Idera Announces New U.S. Patent For Tilsotolimod Through September 2037
9/30/2019 7:40:34 AM
Idera Announces Initiation Of Phase 2 Trial, ILLUMINATE-206
9/4/2019 7:10:00 AM
Idera Pharma Announces Immuno-Oncology Clinical Research Collaboration With AbbVie
7/23/2019 7:37:08 AM
Idera Names Elizabeth Tarka Chief Medical Officer; Promotes John Kirby To CFO
4/10/2019 7:09:07 AM
Idera Pharma Provides Corporate Update
2/27/2019 7:13:43 AM
Idera Pharma Completes Enrollment Into The ILLUMINATE-204 Trial Of The Combination Of Tilsotolimod And Ipilimumab
12/18/2018 4:08:27 PM
Idera Pharmaceuticals Appoints Carol Schafer To Its Board Of Directors
12/14/2018 7:07:16 AM
Idera Pharma Presents Clinical Update From ILLUMINATE-204 Trial Of Combination Of Tilsotolimod And Ipilimumab
9/18/2018 4:02:06 PM
Idera Pharmaceuticals Appoints Howard Pien To Its Board Of Directors